Exelixis | EXEL - Cost Of Sales

Stock Price
44.06
Daily Change
-0.22 -0.50%
Monthly
3.28%
Yearly
13.88%
Q1 Forecast
42.28

Exelixis reported $26.48M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 26.22M 4.58M Dec/2025
Agios Pharmaceuticals USD 1.88M 199K Dec/2025
Akebia Therapeutics USD 8.13M 2.41M Mar/2025
Amgen USD 1.79B 128M Dec/2025
AstraZeneca USD 3.27B 471M Dec/2025
Bayer EUR 4.31B 57M Sep/2025
BioMarin Pharmaceutical USD 161.56M 16.62M Dec/2025
Bristol-Myers Squibb USD 4.92B 657M Dec/2025
Cytokinetics USD 99.23M 13.32M Sep/2025
Eisai JPY 51.08B 5.56B Dec/2025
Eli Lilly USD 3.37B 363.7M Dec/2025
Esperion Therapeutics USD 51.63M 22.2M Sep/2024
Exelixis USD 26.48M 7.91M Dec/2025
Genmab DKK 57M 15M Jun/2025
Glaxosmithkline GBP 3.01B 853.01M Sep/2025
Incyte USD 121.18M 22.18M Dec/2025
Ionis Pharmaceuticals USD 8M 5.66M Dec/2025
MacroGenics USD 44.3M 5.4M Sep/2025
Merck USD 3.32B 531M Dec/2025
Moderna USD 452M 245M Dec/2025
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Neurocrine Biosciences USD 17.6M 246.4M Dec/2025
Novartis USD 3.54B 217M Sep/2025
Pfizer USD 6.29B 2.12B Dec/2025
Puma Biotechnology USD 29.1M 18.44M Sep/2024
Sanofi EUR 3.76B 344M Dec/2025
Takeda JPY 401.15B 184.07B Dec/2025
Ultragenyx Pharmaceutical USD 29M 1.01M Dec/2025
Xencor USD 61.66M 50.95M Jun/2025